

GEARing UP FOR INNOVATION

CURETIS' ACQUISITION OF THE GEAR BioIT PLATFORM AND
DATABASE FROM SIEMENS

Conference Call Presentation
September 8, 2016



WE CARE FOR
DIAGNOSTICS

DISCLAIMER & FORWARD LOOKING STATEMENTS

This document has been issued by Curetis N.V. (the “Company” and, together with its subsidiary, the “Group”) and does not constitute or form part of and should not be construed as any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision, nor does it constitute a recommendation regarding the securities of the Company or any present or future member of the Group.

In particular, this document is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Neither this document nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions or distributed, directly or indirectly, in the United States of America, its territories or possessions or to any US person.

All information contained herein has been carefully prepared. However, no reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers or employees or any other person as to the accuracy or completeness of the information or opinions contained in this document and no liability whatsoever is accepted by the Company or any of its directors, officers or employees nor any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Where third-party information has been used in this document, the source of this information has been identified. The information in this document that has been sourced from third parties has been accurately reproduced and, as far as the Company is aware and able to ascertain from the information published by that third party, the reproduced information is correct. However, the Company has not verified the reproduced information and does not guarantee nor bear or assume responsibility for the accuracy and completeness of the information from third-party sources presented in this document.

The information contained in this presentation is subject to amendment, revision and updating. Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company’s or, as appropriate, senior management’s current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any information contained in this presentation (including forward-looking statements), whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.

By attending, reviewing or consulting the presentation to which this document relates or by accepting this document you will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice.

GEARing UP FOR INNOVATION

SUMMARY OF THE GEAR TRANSACTION

- > Curetis signed GEAR asset acquisition agreement with Siemens on Sep 7, 2016
- > Won competitive bidding process
- > Deal structure minimizes short-term cash impact

The Asset


- > GEAR: GENetic Antibiotic Resistance and Susceptibility Database
- > BioIT Platform & Database
- > Database Content
- > Terabytes of NGS & susceptibility raw data
- > DNA of 11,000+ strains
- > Numerous patents and patent applications
- > Know-how

The Terms

- > World-wide sole commercial rights
- > Methods, Products, Services, ...
- > Human and animal diagnostics & pharmaceuticals, food safety testing
- > Upfront payment
- > Milestone payments upon first regulatory clearance of IVD products
- > Industry-typical royalties on biomarkers and platform
- > NO impact (e.g. royalties) on Curetis' current products or short-term pipeline

WHAT IS GEAR?

A BIOMARKER ENGINE TOWARDS GENETIC ANTIBIOGRAMS



WHAT IS SO UNIQUE ABOUT GEAR?

UNMATCHED SCOPE, IP PORTFOLIO & CONTENT READY TODAY

**Most comprehensive data set on
genotype/phenotype
correlations in the field**

- › Pathogen spectrum & statistical power
- › Drug spectrum and phenotyping depth
- › Sequencing depth & quality

**Scalable, proprietary state-of-
the-art bioinformatics pipeline**

- › Sophisticated raw data processing
- › Multi-layered sequencing quality control (QC)
- › Advanced bioinformatics approaches to
 - › Taxonomic ID (MALDI-TOF verified)
 - › Variant Calling
 - › Genome-wide association with AST data
 - › Classification

Exhaustive IP coverage

- › Bioinformatics methods
- › SNP and gene biomarkers and combinations thereof
- › Biomarker combinations and decision trees

Acquiring the commercial rights to the GEAR assets gives Curetis a head-start of several years in antibiotic resistance biomarker research and paves the way for multiple additional opportunities within its business focus

WHY IS IT A GREAT FIT FOR CURETIS?

STRENGTHENING CURETIS' POSITION AS MDX CONTENT LEADER

- > Faster comprehensive diagnostics delivering actionable results are key to improving management of infectious diseases and limiting inadequate use of antibiotics
- > **Actionable Dx = Pathogen ID + Resistance/Susceptibility Data**

Curetis leads today in genetic antibiotic resistance testing



Pneumonia:
Unyvero P55
 20 Pathogens
 19 Genetic Resistance Markers



Implant & Tissue Infections:
Unyvero ITI
 85 Pathogens
 17 Genetic Resistance Markers



Bloodstream Infections:
Unyvero BCU
 87 Pathogens
 16 Genetic Resistance Markers

GEAR: Further expanding Curetis' leadership position

- > Access to proprietary markers, panels, and algorithms for Unyvero platform
- > Unique resource for Curetis' pharma collaborations
- > Platform to engage in cutting-edge research
 - > Epidemiology of novel strains/resistances
 - > Novel mechanisms of resistance
- > Upside via added business models and outlicensing

GEAR BUSINESS PERSPECTIVES AND VISION



SOPHISTICATED IVD CONTENT FOR CURETIS' UNYVERO PLATFORM

GEAR: A Content Engine for Unyvero

- › GEAR can provide proprietary antibiotic resistance markers for Unyvero Applications
- › GEAR further allows identifying proprietary marker combinations and algorithms for superior accuracy of genetic antibiotic resistance testing
- › GEAR allows designing panels for drug classes and drug combinations for one or multiple pathogens

Unyvero multiplex PCR platform is ideally suited for sophisticated multiparameter genetic antibiotic resistance testing based on markers derived from **GEAR**


Example: Multiparameter Testing



Accuracy		
Individual Features		Combination
★ 79%	★ 64%	100%

GEAR BUSINESS PERSPECTIVES AND VISION


GROWING THE BUSINESS BEYOND UNYVERO



PERSPECTIVES AND VISION: COLLABORATIONS


TOGETHER WITH THE COMMUNITY – AND FOR THE COMMUNITY

In the battle against infectious diseases and spreading antibiotic resistance, Curetis considers GEAR a platform for collaborative research within grant-funded projects



GEAR IMPLEMENTATION ROADMAP

FIRST STEPS



- › **GEAR Team:** Initial core team of BioIT and Project Management Experts to be set-up in early 2017. Reporting to Curetis CCO.
- › **GEAR Location:** At or in close proximity of suitable clinical research institution to foster academic exchange and translation and get access to NGS resources. Discussions with suitable hosts ongoing.

SUMMARY

GEARing-up IS TRANSFORMATIONAL FOR CURETIS

GEAR...

- ... is currently the most comprehensive and sophisticated database and set of IP assets in the field
- ... is immediately synergistic with Curetis' Unyvero platform and core business
- ... transforms Curetis from a platform-focused IVD company to a content innovator
- ... gives Curetis a head-start of several years in proprietary biomarker development
- ... offers multiple additional opportunities within Curetis' business focus
- ... prepares Curetis for the increasingly important role of NGS in infectious disease diagnostics
- ... provides significant upside to the Curetis mid- to long-term equity story at reasonable short-term cost

GEARing up for Innovation

Q&A

Curetis N.V.
Max-Eyth-Str. 42
71088 Holzgerlingen | Germany

Tel.: +49 (0)7031/49195-10
E-Mail: ir@curetis.com
www.curetis.com



THANK YOU!